Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study
TGFβ抑制剂SAR439459单药治疗及联合cemiplimab治疗晚期实体瘤患者的安全性、药代动力学、药效学和抗肿瘤活性：一项1/1b期研究的结果
期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.13854
Baranda, Joaquina C; Robbrecht, Debbie; Sullivan, Ryan; Doger, Bernard; Santoro, Armando; Barve, Minal; Grob, Jean-Jacques; Bechter, Oliver; Vieito, Maria; de Miguel, Maria Jose; Schadendorf, Dirk; Johnson, Melissa; Pouzin, Clemence; Cantalloube, Cathy; Wang, Rui; Lee, Jooyun; Chen, Xiaofei; Demers, Brigitte; Amrate, Amele; Abbadessa, Giovanni; Hodi, F Stephen
